Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROZAC WEEKLY vs Fluoxetine-Safety-Postpartum
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking reuptake of serotonin at the presynaptic neuronal membrane.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder,Premenstrual dysphoric disorder (off-label),Bipolar depression (off-label),Social anxiety disorder (off-label)
90 mg orally once weekly
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
Fluoxetine: 4-6 days after single dose, 4-6 days (extended to 7-9 days with chronic dosing due to autoinhibition of CYP2D6); norfluoxetine: 9-31 days. Steady state achieved after 2-4 weeks.
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
Hepatic via CYP2D6, CYP2C9, and CYP3A4; active metabolite norfluoxetine.
Hepatic via CYP2D6, CYP2C9, CYP3A4; active metabolite norfluoxetine.
Renal excretion of metabolites (primarily fluoxetine glucuronide and norfluoxetine glucuronide) accounts for approximately 80% of elimination; fecal excretion accounts for approximately 15%.
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
Approximately 94.5% bound to plasma proteins, including albumin and alpha-1-acid glycoprotein.
94% bound to albumin and alpha-1-acid glycoprotein
12-43 L/kg (average ~25 L/kg). Large Vd indicates extensive tissue distribution, including brain and fat; contributes to prolonged elimination.
12-43 L/kg; extensive tissue distribution including brain, breast milk.
Oral: ~90% (not significantly affected by food). Weekly formulation: same bioavailability as daily dosing.
Oral: 95% (72% after first-pass); food may slightly decrease rate but not extent.
No dose adjustment required for GFR ≥15 m L/min; insufficient data for GFR <15 m L/min, use with caution.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min), use cautiously with a maximum dose of 40 mg/day.
Child-Pugh Class A: no adjustment; Class B: initiate at 20 mg/day (immediate-release) or use alternative; Class C: contraindicated or use with extreme caution.
Child-Pugh Class A: 20 mg every other day; Class B: 20 mg every third day; Class C: avoid use or use 10 mg every third day with careful monitoring.
Not approved for use in pediatric patients; safety and efficacy not established.
Children (8-12 years): 10-20 mg orally once daily; adolescents (13-17 years): 20 mg orally once daily. Maximum 60 mg/day. Weight-based: 0.5-1.0 mg/kg/day, titrate to maximum 1.5 mg/kg/day.
Initiate with 20 mg/day (immediate-release) and increase cautiously; monitor for hyponatremia and SIADH; PROZAC WEEKLY not recommended due to limited data.
Initial dose 10 mg orally once daily; titrate slowly to a maximum of 40 mg/day due to increased half-life and risk of hyponatremia and QT prolongation.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Clinical worsening and suicide risk,Serotonin syndrome,Mania/hypomania,Seizures,Altered platelet function,Angle-closure glaucoma,Hyponatremia,QT prolongation,Sexual dysfunction
Serotonin syndrome; risk of bleeding; activation of mania/hypomania; hyponatremia; discontinuation syndrome; QT prolongation (overdose).
Concomitant use with MAOIs,Concomitant use with pimozide or thioridazine,Known hypersensitivity to fluoxetine
Concurrent use with MAOIs (or within 14 days); concurrent use with thioridazine or pimozide; known hypersensitivity to fluoxetine.
Grapefruit and grapefruit juice may increase fluoxetine levels; avoid large amounts. No specific dietary restrictions, but take with food if GI upset occurs.
No specific food interactions; avoid grapefruit juice as it may increase fluoxetine levels. Take with or without food; if GI upset occurs, take with food.
First trimester: Crosses placenta; risk of major congenital malformations based on some studies (e.g., cardiovascular defects approx. 1.8% vs 1% baseline). Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN) approx. 0.3% vs 0.1% baseline. Late trimester: Neonatal adaptation syndrome (irritability, feeding difficulties, respiratory distress) in ~30% exposed neonates.
First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/third trimester: Persistent pulmonary hypertension of the newborn (PPHN) risk ~1.5-2 times baseline; risk of preterm birth and low birth weight. Late third trimester: Risk of poor neonatal adaptation syndrome (PNAS) including jitteriness, respiratory distress, feeding difficulties, and irritability.
Fluoxetine and norfluoxetine are excreted in breast milk. Infant serum concentrations are typically low (<10% maternal weight-adjusted dose). M/P ratio for fluoxetine ~0.8; norfluoxetine ~0.2. Cases of adverse effects (fussiness, poor feeding) are rare. Benefits may outweigh risks in moderate-severe depression.
Fluoxetine and its active metabolite norfluoxetine are excreted into breast milk; M/P ratio ~0.3-1.0 for fluoxetine and ~0.5-2.0 for norfluoxetine. Relative infant dose approximately 2-12% of maternal weight-adjusted dose. Cases of colic, irritability, and poor feeding in breastfed infants have been reported. Generally considered compatible with breastfeeding; however, monitor infant for sedation, poor weight gain, and development.
No dose adjustment required based on PK studies in pregnancy. However, due to increased volume of distribution and clearance late in pregnancy, some patients may require a dose increase to maintain efficacy; monitor clinical response and adjust dose as needed.
Pregnancy increases fluoxetine clearance and decreases plasma concentrations, especially in the third trimester. Dose may need to be increased by 20-50% (e.g., from 20 mg to 30-40 mg daily) to maintain therapeutic effect. Consider therapeutic drug monitoring if available. Postpartum, dose should be reduced to pre-pregnancy levels within 48-72 hours due to reversal of pharmacokinetic changes.
Fluoxetine has a long half-life (4-6 days; active metabolite norfluoxetine 4-16 days) allowing weekly dosing, but requires daily loading for 13 weeks before switching to weekly. Monitor for serotonin syndrome if co-prescribed with other serotonergic drugs. Abrupt discontinuation may cause withdrawal symptoms despite long half-life.
Fluoxetine has a long half-life (4-6 days, norfluoxetine 4-16 days) resulting in steady-state after 2-4 weeks; use lower starting doses (10 mg daily) in postpartum women to minimize side effects; monitor for neonatal adaptation syndrome if used in third trimester; consider dose adjustment in hepatic impairment; avoid in breastfeeding unless benefit outweighs risk due to presence in breast milk.
Take once weekly on the same day, typically 90 mg capsule. Do not crush or chew.,May take 4-8 weeks for full therapeutic effect.,Common side effects include nausea, insomnia, drowsiness, sweating, and sexual dysfunction.,Avoid alcohol as it may worsen side effects.,Contact doctor if rash, suicidal thoughts, or serotonin syndrome symptoms occur.,Do not stop abruptly; withdrawal effects possible.
Take fluoxetine exactly as prescribed, typically once daily in the morning.,It may take 4 weeks or longer to feel full benefit; do not stop abruptly.,Common side effects include nausea, headache, insomnia, and sexual dysfunction.,Contact your doctor if you experience rash, unusual bleeding, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not breastfeed without discussing risks with your healthcare provider.
No interactions on record
"Pazopanib, a tyrosine kinase inhibitor, inhibits CYP2D6 activity, leading to reduced metabolism of fluoxetine, a substrate of CYP2D6. This results in increased serum concentrations of fluoxetine and its active metabolite norfluoxetine, elevating the risk of serotonin-related adverse effects such as serotonin syndrome, nausea, and insomnia. The interaction is clinically significant and may require dose adjustment of fluoxetine."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"Concomitant use of tolcapone, a catechol-O-methyltransferase (COMT) inhibitor used in Parkinson's disease, with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), may potentiate serotonergic effects leading to serotonin syndrome, characterized by autonomic instability, neuromuscular hyperactivity, and altered mental status. Additionally, both drugs undergo hepatic metabolism via CYP450 enzymes, and fluoxetine's inhibition of CYP2C9 and CYP3A4 may reduce tolcapone clearance, increasing the risk of hepatotoxicity and other adverse effects. The combination requires careful monitoring for signs of serotonin toxicity and liver injury."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROZAC WEEKLY vs Fluoxetine-Safety-Postpartum, answered by our medical review team.
PROZAC WEEKLY is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking reuptake of serotonin at the presynaptic neuronal membrane.. Fluoxetine-Safety-Postpartum is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROZAC WEEKLY and Fluoxetine-Safety-Postpartum depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROZAC WEEKLY is: 90 mg orally once weekly. The standard adult dose of Fluoxetine-Safety-Postpartum is: 20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROZAC WEEKLY and Fluoxetine-Safety-Postpartum in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROZAC WEEKLY is classified as Category C. First trimester: Crosses placenta; risk of major congenital malformations based on some studies (e.g., cardiovascular defects approx. 1.8% vs 1% baseline). Third trimester: Risk of. Fluoxetine-Safety-Postpartum is classified as Category A/B. First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.